GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Total Long-Term Liabilities

RemeGen Co (HKSE:09995) Total Long-Term Liabilities : HK$1,414 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. RemeGen Co's Total Long-Term Liabilities for the quarter that ended in Dec. 2024 was HK$1,414 Mil.


RemeGen Co Total Long-Term Liabilities Historical Data

The historical data trend for RemeGen Co's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Total Long-Term Liabilities Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Liabilities
Get a 7-Day Free Trial 108.80 118.02 165.93 1,042.85 1,413.84

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 165.93 727.03 1,042.85 1,551.84 1,413.84

RemeGen Co Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.


RemeGen Co Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.
Executives
I-nova Limited 2101 Beneficial owner
Yantai Rongda Venture Capital Center (limited Partnership) 2103 Interests held jointly with another person
Yang Minhua 2103 Interests held jointly with another person
Xiong Xiaobin 2103 Interests held jointly with another person
Wen Qingkai 2103 Interests held jointly with another person
Deng Yong 2103 Interests held jointly with another person
Fang Jianmin 2103 Interests held jointly with another person
Lin Jian 2103 Interests held jointly with another person
Rongchang Holding Group Ltd. 2103 Interests held jointly with another person
Wang Liqiang 2103 Interests held jointly with another person
Wang Weidong 2201 Interest of corporation controlled by you
Wang Xudong 2103 Interests held jointly with another person
Wei Jianliang 2103 Interests held jointly with another person
Morgan Stanley 2201 Interest of corporation controlled by you
Allianz Se 2201 Interest of corporation controlled by you

RemeGen Co Headlines

No Headlines